Axillary node staging for microinvasive breast cancer: Is it justified?
Carcinoma in Situ
Carcinoma, Ductal, Breast
Lymph Node Excision
Neoplasm Recurrence, Local
Our results suggest that SLN biopsy may be justified for DCISM, but is clearly most beneficial to identify a very small subset of DCISM patients (2.7%, with SLN macrometastasis) who could benefit from systemic adjuvant therapy. The benefit of SLN biopsy for patients with SLN micrometastases/ITCs (pN0mi or pN0(i+)) is uncertain, and in these cases ALND does not appear to be warranted. We suggest a wider reappraisal of routine SLN biopsy for DCISM.